Idorsia Pharmaceutical Ltd (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.
Headquarters
Switzerland
Address
Hegenheimermattweg 91, Allschwil, 4123
Website
www.idorsia.com
Telephone
41 58 8440000
No of Employees
1,361
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IDIA (SWF)
Revenue (2021)
$101.7M
174.7%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-30.5%
(2021 vs 2020)
Market Cap*
$424.0M
Net Profit Margin (2021)
XYZ
52.5%
(2021 vs 2020)
* As of and is in US$
Idorsia Pharmaceutical Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Daridorexant- Insomnia |
| Aprocitentan- Resistant Hypertension |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received US FDA approval for TRYVIO (aprocitentan) for the treatment of high blood pressure. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Viatris Inc to secure global development and commercialization rights to two Phase 3 assets and the potential to add additional innovative assets. |
| 2023 | Contracts/Agreements | In June, Idorsia Ltd announced the availability of QUVIVIQ to patients in Switzerland for the treatment of adult patients with chronic insomnia. |
Competitor Comparison
| Key Parameters | Idorsia Pharmaceutical Ltd | Adienne Pharma & Biotech SA | Carbogen Amcis AG | SeneXta Therapeutics SA |
|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Switzerland |
| City | Allschwil | Lugano | Bubendorf | Lugano |
| State/Province | - | Tessin | Basel-Landschaft | Tessin |
| No. of Employees | 1,361 | - | - | - |
| Entity Type | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mathieu Simon | Chairman | Executive Board | 2020 | 67 |
| Jean-Paul Clozel | Director; Chief Executive Officer | Executive Board | 2017 | 68 |
| Andre C. Muller | Chief Financial Officer; Executive Vice President | Senior Management | 2017 | 60 |
| Guy Braunstein | Executive Vice President; Chief Medical Officer | Senior Management | 2022 | 67 |
| Martine Clozel | Executive Vice President; Chief Scientific Officer | Senior Management | 2017 | 68 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward